Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial

Background: No standard chemotherapy is used as neoadjuvant therapy in triple negative breast cancer (TNBC). This study has compared carboplatin plus paclitaxel with commonly used epirubicin plus paclitaxel as neoadjuvant chemotherapy (NAC) in TNBC. Results: 91 patients with a median age of 47 years...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Zhang, Pin, Yin, Yi, Mo, Hongnan, Zhang, Bailin, Wang, Xiang, Li, Qing, Yuan, Peng, Wang, Jiayu, Zheng, Shan, Cai, Ruigang, Ma, Fei, Fan, Yin, Xu, Binghe
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Clinical Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5312408/
https://ncbi.nlm.nih.gov/pubmed/27447966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10607
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky